CLIN CANCER RES：Binimetinib联合紫杉醇治疗铂类耐药卵巢癌

2018-11-20 MedSci MedSci原创

上皮性卵巢癌（EOC）是一种分子表型多样的肿瘤。MEK抑制靶向存在MAPK通路改变的肿瘤并增强紫杉醇诱导的细胞凋亡。CLIN CANCER RES近期发表了一篇文章，评估MEK抑制剂binimetinib联合紫杉醇治疗铂类耐药EOC患者的疗效。

上皮性卵巢癌（EOC）是一种分子表型多样的肿瘤。MEK抑制靶向存在MAPK通路改变的肿瘤并增强紫杉醇诱导的细胞凋亡。CLIN CANCER RES近期发表了一篇文章，评估MEK抑制剂binimetinib联合紫杉醇治疗铂类耐药EOC患者的疗效。

患者接受三种不同的静脉注射紫杉醇联合口服binimetinib给药方案。通过RECIST和CGIC CA-125反应标准评估结果。通过二代测序分析肿瘤样品。紫杉醇80mg / m 2静脉注射每周联合binimetinib30mg每天两次连续给药或45mg每天两次间间断性给药被确认是推荐II期试验剂量（RP2D）。3/4级不良反应发生率为65％。最佳总体反应率为18％，28例RECIST可测量疾病的患者中，1例完全缓解（CR）4，例部分缓解（PR），11，例患者达到稳定疾病（SD），临床获益率（CR + PR + SD）为57％。45mg每天两次的连续队列中RECIST和CA-125标准的缓解率在最高，45mg每天两次的间歇性队列中最低。4例存在MAPK通路改变的肿瘤患者均出现临床获益。

文章最后认为，binimetinib联合静脉注射紫杉醇耐受性良好。Binimetinib联合紫杉醇的RP2D为连续给药30mg，一天两次或间断给药45mg，每天两次。尽管患者缓解率情况一般，但存在影响MAPK通路的改变的患者中观察到了更高的临床获益率。

原始出处：

Zeynep Eroglu, Y. Ann Chen, et al. Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma. CLIN CANCER RES. November 2018 doi: 10.1158/1078-0432.CCR-18-0565

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1896423, encodeId=b3ba1896423c6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Dec 31 13:26:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814989, encodeId=305118149893a, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue Sep 10 13:26:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737595, encodeId=05d51e37595f3, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Apr 23 14:26:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665203, encodeId=688a1665203fb, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3417, encryptionId=565f341e8a, topicName=binimetinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f1a25912110, createdName=12498e0fm86暂无昵称, createdTime=Wed Jul 17 01:26:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353436, encodeId=ad9935343649, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Nov 23 10:23:43 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568599, encodeId=64e71568599cf, content=<a href='/topic/show?id=139f9658680' target=_blank style='color:#2F92EE;'>#铂类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96586, encryptionId=139f9658680, topicName=铂类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eed15401054, createdName=fengxx, createdTime=Thu Nov 22 07:26:00 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
2018-12-31 一闲

#MET#

23 0
[GetPortalCommentsPageByObjectIdResponse(id=1896423, encodeId=b3ba1896423c6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Dec 31 13:26:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814989, encodeId=305118149893a, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue Sep 10 13:26:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737595, encodeId=05d51e37595f3, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Apr 23 14:26:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665203, encodeId=688a1665203fb, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3417, encryptionId=565f341e8a, topicName=binimetinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f1a25912110, createdName=12498e0fm86暂无昵称, createdTime=Wed Jul 17 01:26:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353436, encodeId=ad9935343649, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Nov 23 10:23:43 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568599, encodeId=64e71568599cf, content=<a href='/topic/show?id=139f9658680' target=_blank style='color:#2F92EE;'>#铂类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96586, encryptionId=139f9658680, topicName=铂类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eed15401054, createdName=fengxx, createdTime=Thu Nov 22 07:26:00 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
2019-09-10 yangfl06

#铂类耐药#

46 0
[GetPortalCommentsPageByObjectIdResponse(id=1896423, encodeId=b3ba1896423c6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Dec 31 13:26:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814989, encodeId=305118149893a, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue Sep 10 13:26:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737595, encodeId=05d51e37595f3, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Apr 23 14:26:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665203, encodeId=688a1665203fb, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3417, encryptionId=565f341e8a, topicName=binimetinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f1a25912110, createdName=12498e0fm86暂无昵称, createdTime=Wed Jul 17 01:26:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353436, encodeId=ad9935343649, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Nov 23 10:23:43 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568599, encodeId=64e71568599cf, content=<a href='/topic/show?id=139f9658680' target=_blank style='color:#2F92EE;'>#铂类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96586, encryptionId=139f9658680, topicName=铂类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eed15401054, createdName=fengxx, createdTime=Thu Nov 22 07:26:00 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
2019-04-23 ms3153534357578991

#铂#

20 0
[GetPortalCommentsPageByObjectIdResponse(id=1896423, encodeId=b3ba1896423c6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Dec 31 13:26:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814989, encodeId=305118149893a, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue Sep 10 13:26:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737595, encodeId=05d51e37595f3, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Apr 23 14:26:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665203, encodeId=688a1665203fb, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3417, encryptionId=565f341e8a, topicName=binimetinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f1a25912110, createdName=12498e0fm86暂无昵称, createdTime=Wed Jul 17 01:26:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353436, encodeId=ad9935343649, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Nov 23 10:23:43 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568599, encodeId=64e71568599cf, content=<a href='/topic/show?id=139f9658680' target=_blank style='color:#2F92EE;'>#铂类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96586, encryptionId=139f9658680, topicName=铂类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eed15401054, createdName=fengxx, createdTime=Thu Nov 22 07:26:00 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
2019-07-17 12498e0fm86暂无昵称

#binimetinib#

28 0
[GetPortalCommentsPageByObjectIdResponse(id=1896423, encodeId=b3ba1896423c6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Dec 31 13:26:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814989, encodeId=305118149893a, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue Sep 10 13:26:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737595, encodeId=05d51e37595f3, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Apr 23 14:26:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665203, encodeId=688a1665203fb, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3417, encryptionId=565f341e8a, topicName=binimetinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f1a25912110, createdName=12498e0fm86暂无昵称, createdTime=Wed Jul 17 01:26:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353436, encodeId=ad9935343649, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Nov 23 10:23:43 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568599, encodeId=64e71568599cf, content=<a href='/topic/show?id=139f9658680' target=_blank style='color:#2F92EE;'>#铂类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96586, encryptionId=139f9658680, topicName=铂类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eed15401054, createdName=fengxx, createdTime=Thu Nov 22 07:26:00 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
2018-11-23 一天没事干

很好的学习机会

81 0
[GetPortalCommentsPageByObjectIdResponse(id=1896423, encodeId=b3ba1896423c6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Dec 31 13:26:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814989, encodeId=305118149893a, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue Sep 10 13:26:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737595, encodeId=05d51e37595f3, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Tue Apr 23 14:26:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665203, encodeId=688a1665203fb, content=<a href='/topic/show?id=565f341e8a' target=_blank style='color:#2F92EE;'>#binimetinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3417, encryptionId=565f341e8a, topicName=binimetinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f1a25912110, createdName=12498e0fm86暂无昵称, createdTime=Wed Jul 17 01:26:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353436, encodeId=ad9935343649, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Nov 23 10:23:43 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568599, encodeId=64e71568599cf, content=<a href='/topic/show?id=139f9658680' target=_blank style='color:#2F92EE;'>#铂类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96586, encryptionId=139f9658680, topicName=铂类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eed15401054, createdName=fengxx, createdTime=Thu Nov 22 07:26:00 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
2018-11-22 fengxx

#铂类#

34 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

CLIN CANCER RES：Binimetinib联合紫杉醇治疗铂类耐药卵巢癌

相关资讯

科室

工具

服务